Three patient outcomes were measured in this new study: time to onset of ocular-related myasthenia gravis, Activities of ...

The FDA has approved Alexion's Soliris for use in patients with treatment resistant generalised Myasthenia gravis (gMG), making it the first new therapy for the condition in 60 years. The approval ...

Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis ...

New biomarkers enhance multiple sclerosis (MS) diagnosis, enabling earlier detection and improved patient care, transforming ...